ElizabethKatherineLeeMD

Oncology • Boston, MA

Gynecologic Cancer

Instructor, Medical Gynecologic Oncology

Join to view full profile

Dr. Lee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lee's full profile

Already have an account?

Office
450 Brookline Ave
# Dana-Far
Boston, MA 02215
Phone+1 617-632-6094

Fax+1 617-632-3479

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2020
Johns Hopkins UniversityResidency, Internal Medicine, 2014 - 2017
University of Pittsburgh School of MedicineClass of 2014

Certifications & Licensure

MA State Medical License 2017 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

2 citations
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, Martin Højgaard, Niharika B Mettu
Journal of the National Cancer Institute. 2024-09-01
Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies.
Elizabeth K Lee, Joyce F Liu
Clinical Advances in Hematology & Oncology. 2024-08-07
2 citations
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre André B A da Costa, Doga Gulhan
JCO Precision Oncology. 2024-04-01

Journal Articles

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.
Lee EK, Lindeman NI, Matulonis UA, Konstantinopoulos PA, Gynecologic Oncology Reports, 5/2019

Press Mentions

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical TrialSeptember 15th, 2024
Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024September 11th, 2024

Professional Memberships